Literature DB >> 23244227

Cardiovascular diseases in patients with rheumatoid arthritis.

R Koivuniemi1, L Paimela, R Suomalainen, M Leirisalo-Repo.   

Abstract

OBJECTIVES: To study cardiovascular autopsy findings and the lifetime prevalence of cardiovascular diseases (CVDs) in patients with rheumatoid arthritis (RA).
METHOD: In 369 RA patients and their reference cases without any rheumatic disease (non-RA), we studied CVDs recorded on autopsy reports at consecutive autopsies from 1952 to 1991. From autopsy referrals by clinicians, we recorded lifetime CVDs. In RA patients autopsied from 1973, we evaluated clinical data.
RESULTS: From 1952 to 1991, RA patients had, compared with non-RA, myocardial infarction (MI; 26% vs. 41%) and cerebral infarction (14% vs. 28%) less frequently but cardiac amyloidosis (28% vs. 3%), pericarditis (27% vs. 8%), and diffuse myocardial abnormality (21% vs. 11%) more frequently reported at autopsy. Of RA patients autopsied from 1973, 40% had had a diagnosis of congestive heart failure (CHF) and coronary heart disease (CHD) during their lifetime. The RA patients with CHF had a higher mean erythrocyte sedimentation rate (ESR) than those without CHF. In RA patients, MI or myocardial abnormality at autopsy had no such correlation. In RA, male sex, ischaemic electrocardiogram changes, diabetes, hypertensive disease, and severe radiographic changes typical for RA were associated with MI detected at autopsy. No such associations emerged with respect to diffuse myocardial abnormality. When disorders potentially causing diffuse myocardial damage were excluded, RA patients had, on autopsy reports, compared to non-RA, diffuse myocardial abnormality more frequently (21% vs. 12%, p = 0.002). Cardiac amyloidosis showed no correlation to this.
CONCLUSION: RA patients seem to have an increased risk for myocardial damage. The influence of inflammation on the myocardium in RA needs further studies.

Entities:  

Mesh:

Year:  2012        PMID: 23244227     DOI: 10.3109/03009742.2012.723747

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

Review 1.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 2.  Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?

Authors:  Carmen García-Gómez; Maria Bianchi; Diana de la Fuente; Lina Badimon; Teresa Padró; Emili Corbella; Xavier Pintó
Journal:  World J Orthop       Date:  2014-07-18

Review 3.  Untying the correlation between apolipoproteins and rheumatoid arthritis.

Authors:  Rashita Makkar; Tapan Behl; Arun Kumar; Md Sahab Uddin; Simona Bungau
Journal:  Inflamm Res       Date:  2020-10-14       Impact factor: 4.575

Review 4.  The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Leena R Baghdadi; Richard J Woodman; E Michael Shanahan; Arduino A Mangoni
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

5.  Barriers and facilitators to physical activity in people with an inflammatory joint disease: a mixed methods study.

Authors:  Kirsty Bell; Monserrat Conde; Gordon Hendry; Danny Rafferty; Martijn Steultjens
Journal:  BMC Musculoskelet Disord       Date:  2022-10-05       Impact factor: 2.562

6.  Significant association between TAP2 polymorphisms and rheumatoid arthritis: a meta-analysis.

Authors:  Dongjun Dai; Yong Chen; Ping Ru; Xingyu Zhou; Jianmin Tao; Huadan Ye; Qingxiao Hong; Linlin Tang; Guanghui Pan; Danfeng Lin; Qiongyao Gong; Yuelong Lv; Leiting Xu; Shiwei Duan
Journal:  Diagn Pathol       Date:  2014-06-27       Impact factor: 2.644

7.  Cardiovascular disease is increased prior to onset of rheumatoid arthritis but not osteoarthritis: the population-based Nord-Trøndelag health study (HUNT).

Authors:  Helen Pahau; Matthew A Brown; Sanjoy Paul; Ranjeny Thomas; Vibeke Videm
Journal:  Arthritis Res Ther       Date:  2014-04-02       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.